Hematopoietic Stem Cell Transplantation in CSF1R-Related Leukoencephalopathy: Retrospective Study on Predictors of Outcomes

Mutations in the CSF1R gene are the most common cause of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a neurodegenerative disease with rapid progression and ominous prognosis. Hematopoietic stem cell transplantation (HSCT) has been increasingly offered to patients with CSF1R-ALSP. However, different therapy results were observed, and it was not elucidated which patient should be referred for HSCT. This study aimed to determine predictors of good and bad HSCT outcomes in CSF1R-ALSP. We retrospectively analyzed 15 patients, 14 symptomatic and 1 asymptomatic, with CSF1R-ALSP that underwent HSCT. Median age of onset was 39 years, and the median age of HSCT was 43 years. Cognitive impairment was the most frequent initial manifestation (43%), followed by gait problems (21%) and neuropsychiatric symptoms (21%). Median post-HSCT follow-up was 26 months. Good outcomes were associated with gait problems as initial (p = 0.041) and predominant (p = 0.017) manifestation and younger age at HSCT (p = 0.044). Cognitive impairment as first manifestation was a predictor of a bad outcome (p = 0.016) and worsening of cognition post-HSCT (p = 0.025). In conclusion, gait problems indicated a milder phenotype with better response to HSCT and good therapy outcomes. In contrast, patients with a higher burden of cognitive symptoms were most likely not to benefit from HSCT.

[1]  R. Benedict,et al.  Cognitive Relapse in Multiple Sclerosis: New Findings and Directions for Future Research , 2022, NeuroSci.

[2]  Patrycja Mensah-Glanowska,et al.  The First Allogeneic Hematopoietic Stem Cell Transplantation in a Polish Patient with Adult‐Onset Leukoencephalopathy with Spheroids and Pigmented Glia , 2022, Movement disorders : official journal of the Movement Disorder Society.

[3]  T. Prescott,et al.  Prophylactic Allogeneic Hematopoietic Stem Cell Therapy for CSF1R ‐Related Leukoencephalopathy , 2022, Movement disorders : official journal of the Movement Disorder Society.

[4]  D. Dickson,et al.  Neuropathological Findings of CSF1R‐Related Leukoencephalopathy After Long‐Term Immunosuppressive Therapy , 2022, Movement disorders : official journal of the Movement Disorder Society.

[5]  F. Eichler,et al.  Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia: Review of Clinical Manifestations as Foundations for Therapeutic Development , 2022, Frontiers in Neurology.

[6]  Z. Wszolek,et al.  Neuroimaging phenotypes of CSF1R‐related leukoencephalopathy: Systematic review, meta‐analysis, and imaging recommendations , 2021, Journal of internal medicine.

[7]  Jiangxia Wang,et al.  Predictors of cognitive impairment in pseudotumor cerebri. , 2021, Neurologia i neurochirurgia polska.

[8]  E. Middlebrooks,et al.  Treatment of CSF1R‐Related Leukoencephalopathy: Breaking New Ground , 2021, Movement disorders : official journal of the Movement Disorder Society.

[9]  Z. Wszolek First Polish case of CSF1R-related leukoencephalopathy. , 2021, Neurologia i neurochirurgia polska.

[10]  Patrycja Mensah-Glanowska,et al.  Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia associated with an A792D mutation in the CSF1R gene in a Polish patient. , 2021, Neurologia i neurochirurgia polska.

[11]  Ahmed Esmael,et al.  Prevalence of cognitive impairment in acute ischaemic stroke and use of Alberta Stroke Programme Early CT Score (ASPECTS) for early prediction of post-stroke cognitive impairment. , 2021, Neurologia i neurochirurgia polska.

[12]  Z. Wszolek,et al.  Microglial replacement therapy: a potential therapeutic strategy for incurable CSF1R-related leukoencephalopathy , 2020, Acta Neuropathologica Communications.

[13]  C. Hess,et al.  Allogeneic HSCT for adult-onset leukoencephalopathy with spheroids and pigmented glia. , 2019, Brain : a journal of neurology.

[14]  W. Libionka,et al.  The impact of subthalamic deep brain stimulation on sleep and other non-motor symptoms in Parkinson's disease. , 2019, Parkinsonism & related disorders.

[15]  S. Lehéricy,et al.  Haematopoietic stem cell transplantation in CSF1R-related adult-onset leukoencephalopathy with axonal spheroids and pigmented glia , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

[16]  D. Dickson,et al.  CSF1R-related leukoencephalopathy , 2018, Neurology.

[17]  W. Libionka,et al.  The impact of subthalamic deep brain stimulation on polysomnographic sleep pattern in patients with Parkinson's disease - Preliminary report. , 2018, Neurologia i neurochirurgia polska.

[18]  J. Satoh,et al.  Adult onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) and Nasu-Hakola disease: Lesion staging and dynamic changes of axons and microglial subsets , 2017, Journal of the Neurological Sciences.

[19]  J. Snowden,et al.  Long-term outcomes of allogeneic haematopoietic stem cell transplantation for adult cerebral X-linked adrenoleukodystrophy , 2017, Brain : a journal of neurology.

[20]  Z. Wszolek,et al.  Clinical and genetic characterization of adult‐onset leukoencephalopathy with axonal spheroids and pigmented glia associated with CSF1R mutation , 2016, European journal of neurology.

[21]  J. Lane,et al.  CSF1R mosaicism in a family with hereditary diffuse leukoencephalopathy with spheroids. , 2016, Brain : a journal of neurology.

[22]  J. Sharma,et al.  SLEEP DISORDERS IN PARKINSON'S DISEASE , 2003, International journal of clinical practice.